Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Vx001 Vaccine in HLA-A*0201 Positive Patients With TERT Positive Stage IV or Recurrent Stage I-III NSCLC

NCT01935154 is registered in ClinicalTrials.gov with Vaxon Biotech as lead sponsor.

NCT NCT01935154
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01935154 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Vx001 Vaccine in HLA-A*0201 Positive Patients With TERT Positive Stage IV or Recurrent Stage I-III NSCLC
Lead sponsor
Vaxon Biotech
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2012
Completion date
January 31, 2017
Enrollment
221 (actual)
Sites
70

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer metastatic